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SUMMARY
We applied digital spatial profiling for 87 immune and stromal genes to lymph
node germinal center (GC) dark- and light-zone (DZ/LZ) regions of interest to
obtain a differential signature of these two distinct microenvironments. The
spatially resolved 53-genes signature, comprising key genes of the DZmutational
machinery and LZ immune and mesenchymal milieu, was applied to the transcrip-
tomes of 543 GC-related diffuse large B cell lymphomas and double-hit (DH) lym-
phomas. According to the DZ/LZ signature, the GC-related lymphomas were sub-
classified into two clusters. The subgroups differed in the distribution of DH cases
and survival, with most DH displaying a distinct DZ-like profile. The clustering
analysis was also performed using a 25-genes signature composed of genes posi-
tively enriched in the non-B, stromal sub-compartments, for the first time
achieving DZ/LZ discrimination based on stromal/immune features. The report
offers new insight into the GC microenvironment, hinting at a DZ microenviron-
ment of origin in DH lymphomas.
INTRODUCTION
Within the category of aggressive B cell lymphomas, diffuse large B cell lymphomas (DLBCL) and high-
grade lymphomas (HGBL) with or without MYC, BCL2, and/or BCL6 (indicated as double- or triple-hit,
DH/TH lymphomas) gene rearrangements are comprised. DLBCL represent a highly heterogeneous dis-
ease entity that encompasses both lymphomas expressing germinal center (GC) B cell markers and others
lacking signs of GC transit (the distinction underlying the cell of origin—COO—classification of DLBCL)
(Alizadeh et al., 2000). The distinction between the GC and non-GC DLBCL refers to genetic, epigenetic
and transcriptional, and phenotypic differences, which, all together, impact on the clinical course, prog-
nosis, and response to treatment (Chapuy et al., 2018; Schmitz et al., 2018). Although generally GC-DLBCL
have a more favorable prognosis, a considerable proportion of them display a more aggressive course
(Pasqualucci and Dalla-Favera, 2018). Recently, Wright and co-workers, using the LymphGen algorithmic
tool to classify DLBCL, highlighted that GC-DLBCL genetic subtypes (defined by mutational patterns)
are strikingly different in the response to standard immuno-chemotherapy and possibly to targeted ther-
apies (Wright et al., 2020). The heterogeneous clinical behavior of GC-related aggressive B cell lymphomas
has been partly explained by the inclusion in this group of DH cases (Ennishi et al., 2019a). DH HGBL have
significantly unfavorable outcomes and show poor response to conventional immuno-chemotherapy reg-
imens; the different course of these lymphomas has been mostly ascribed to the peculiar biology of the B
cell clones undergoing lymphomagenesis, but no clues have so far emerged regarding the stromal/im-
mune imprint of DH (Scott et al., 2015). Here, we aimed at probing in situ distinct immune and stromal
gene expression signatures in two functionally compartmentalized regions of the non-neoplastic GC,
namely, the dark zone (DZ) and the light zone (LZ), in which B cell proliferation, immunoglobulin genes’ so-
matic hypermutation, and antigen-driven B cell selection events occur. In situ gene expression was inves-
tigated to achieve a differential signature of the two microenvironments, which included genes involved in
B cell proliferation and mutational activity, myeloid cell activation, antigen presentation and suppressive/
regulatory functions, T cell identity and immune checkpoint, follicular dendritic cell (FDC) and other
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mesenchymal cell markers, and cytokine and chemokine signaling. Through a spatially resolved region of
interest (ROI) selection-based approach, we investigated transcriptional features reflective of biological
differences in the regulation of B cell/stroma interfaces within the DZ and LZ functional microenvironments
of the non-neoplastic GC. The resulting signature was applied to GC-related DLBCL and HGBL transcrip-
tomes to establish a possible relationship with the GC microenvironment of origin. Our hypothesis-driven
experiment sheds light on the underlying heterogeneity of GC-related aggressive lymphomas, revealing
an immunologically cold DZ-like microenvironment characteristic of DH lymphomas.
RESULTS
ROIs were identified and selected on reactive lymph nodes characterized by follicular hyperplasia and
clear-cut DZ/LZ polarization, based on multiplexed immunofluorescence on a Nanostring GeoMx Digital
Spatial Profiler (Nanostring Technologies Inc., USA). GCs and extra-follicular regions were identified ac-
cording to the expression of the CD20 B cell marker, the FDC meshwork highlighted by CD271 (NGFR),
and the reticular fibroblastic cell meshwork highlighted by smooth muscle actin. Within polarized GC
foci, DZ and LZ ROIs were selected and segmented for ROI-targeted gene expression (Figures 1A–1C).
A customized version of the Human Immuno-Oncology RNA Panel including 87 immune and stromal genes
was developed and applied using a Nanostring GeoMx (Merritt et al., 2020). A list of the 87 genes and of
their main biological pathways according to Gene Ontology Annotation (https://www.ebi.ac.uk/GOA/) is
reported in Table S1.
Based on the differential gene expression, 53 genes significantly discriminated between DZ and LZ ROIs.
Unsupervised clustering analysis of normalized gene expression profiles within unsegmented ROIs (n = 10)
was performed, which highlighted sharp DZ and LZ separation (Figure 1B and Table S2). Among these
genes, those involved in cell proliferation, somatic hypermutation, and chromatin remodeling, such as
AICDA,MKI67,H3F3B, andOAZ1, were upregulated in the DZ ROIs, consistently with the DZ being a tissue
microenvironment hosting GC B cell proliferation and immunoglobulin gene hypermutation events
induced by activation-induced cytidine deaminase (AID) activity. The expression of the histone H3 in the
GC DZ and LZ was probed at the protein level using a double-marker immunofluorescence approach,
which highlighted the bright fluorescence signal of H3 in Ki-67+ DZ cells (Figure 2A), indicating the asso-
ciation of H3 expression with cell replication in the DZ. Genes involved in antigen presentation by major
histocompatibility complex (MHC) classes I and II (B2M, CD74, HLA-E, HLA-DRB1, and HLA-DQA1), im-
mune checkpoints (TIGIT, CTLA4, LAG-3, PDCD1, and PDCD1LG2), and FDC biology (CLU, CXCL13,
and VCAM1) were upregulated in the LZ ROIs, in view of the ongoing immune recognition and selection
dynamics characterizing the LZ. The transcriptional regulator MYC also resulted significantly upregulated
in the LZ, and its spatial enrichment was validated at the protein level by triple-marker immunostaining
including CD20 and Ki-67, which revealed that, within the GC, the scattered MYC+ elements were predom-
inantly localized within the Ki-67-low areas corresponding to the LZ (Figure 2B). Among the genes predom-
inantly expressed in the LZ ROIs, we found the transcript relative to the adhesion receptor CD44, originally
retained, to be differentially expressed in LZ and DZ B cells (Kremmidiotis and Zola, 1995). Interestingly,
CD44 protein expression was not observed as a differential feature of the LZ B cell subset purified by
cell sorting in the seminal study by Victora and colleagues, which provided reference DZ and LZ B cell pro-
files for classification of B cell malignancies (Victora et al., 2012). The positive enrichment of CD44 in the LZ
was validated in situ, by a triple-marker immunolocalization analysis, which showed that CD44 expression
was stronger in the CD20+Ki-67- LZ than in the CD20+Ki-67+ DZ B cells within the GC (Figure 2C). This result
highlights the relevance of spatial profiling in the exploration of transcriptional network elements possibly
controlled in their expression by the cross talk between different cell types sharing the same microenviron-
ment, as in the case of B cell and accessory cells (T, myeloid, and mesenchymal) populating the LZ. To bet-
ter investigate the contribution of B cell-intrinsic and B cell-extrinsic (i.e., stromal and immune) transcripts
to the DZ/LZ discrimination, we analyzed the expression of the 53 DZ/LZ differentially expressed genes in
15 additional ROIs relative to DZ and LZ regions to which B-cell (CD20+NGFR-) and stromal (CD20-NGFR+
and CD20-NGFR-) sub-compartment segmentation masks were applied (Figure 1C). Among the genes
differentially expressed between DZ and LZ ROIs, we identified a list of 25 genes that showed significant
upmodulation in the stromal sub-compartment masks when compared with the B cell masks (Figures 1C
and S1, Table S3). These 25 genes, hereinafter referred to as stromal signature, included key genes regu-
lating T cell identity and activation, such as CD3E, CD4, CD8A, FOXP3, CD40L, 4-1BB, B7-H3, VISTA,
CTLA4, and TIM3; genes related with myeloid/macrophage regulatory function such as IL-15, IDO1, and
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Interestingly, two of the myeloid cytokines included in the stromal signature have a consolidated immuno-
regulatory/suppressive function (IDO1 and ARG1), whereas IL-15 has been involved in the induction of a T
follicular helper phenotype (Cooley et al., 2015). Besides the 25-genes stromal signature, 26 genes were not
significantly modulated between the B cell and stromal sub-compartment masks (e.g., CD44, ICAM1,
CD40, STAT3), and only two genes (CD20 and MKI67) were significantly upregulated in the B cell masks
(Figures 1B, 1C, and S1, Table S3). This result indicated that several genes included in the 53-genes DZ/
LZ signature and contributed by B cells were also expressed by other stromal elements (e.g., ICAM1).
Accordingly, ICAM-1 in situ protein validation by triple-marker immunolocalization analysis in combination
Figure 1. Identification of a DZ/LZ Microenvironment Differential Signature by Digital Spatial Profiling on
Reactive Lymph Node ROIs
(A) Multiplexed immunofluorescence for CD20 (red signal), nerve growth factor receptor (NGFR)/CD271 (cyan signal),
smooth muscle actin (SMA, green signal), and Syto83 (blue signal) has been performed to drive selection of ROIs
corresponding to LZ and DZ, for segmentation and gene expression analysis. Scale bar, 250 micrometers.
(B) Unsupervised clustering of the gene expression profiles generated from DZ and LZ segmented ROIs according to a
custom mRNA panel, showing the separation of DZ and LZ ROIs based on the expression of the 53 deregulated genes.
(C) DZ and LZ ROIs segmentation with the application of masks for B cells (CD20+NGFR), FDCs (CD20NGFR+), and
other stromal and immune components (CD20-NGFR) allows identification of genes significantly upmodulated in B cells
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with Ki-67 and CD20 showed modulation between the DZ and LZ with a higher expression in the latter,
where it showed co-localization with CD20 in B cells and also expression in CD20- stromal elements (Fig-
ure 2D, arrowheads).
We then investigated whether genes modulated in our spatial DZ/LZ profiling could be found consis-
tently modulated between the transcriptional profiles of DZ and LZ from purified human B cells identified
by Victora et al. (2012). To this aim, we performed an unsupervised clustering analysis of their dataset,
using our 53-genes DZ/LZ spatial signature. Interestingly, our signature assigned samples in total agree-
ment with Victora’s groups. We could verify the shared and concordant modulation of KI-67, AICDA, and
POLH that were higher in DZ B cells and of BART3, ICAM-1, HLA-DQA1, CD40, CD44, ITGB2, and MYC
that showed higher expression in LZ B cells (Figures 3A and 3B). We also assessed whether the 25-genes
stromal signature that we derived from transcripts significantly enriched in non-B spatial sub-compart-
ments (CD20NGFR+ and CD20NGFR-) when compared with B cell sub-compartments (CD20+NGFR)
had overlap with the differential DZ/LZ B cell genes reported by Victora et al. Indeed, none of the 25
genes were found among the DZ/LZ B cell differential genes. Nonetheless, the clustering of the Victora
et al. samples according to our 25-genes stromal signature was consistent (Figures 3C and 3D). Promp-
ted by the successful discrimination of DZ/LZ ROIs according to the spatial 53-genes signature, we aimed
Figure 2. In Situ Protein Validation of Selected Markers from DZ/LZ Differential Gene Signature in Reactive
Lymph Node GCs
(A) Double-marker immunofluorescence analysis of Histone H3 expression in the GC showing bright nuclear expression of
H3 (green signal) in Ki-67+ (red signal) proliferating cells within the GC DZ.
(B) Triple-marker combined immunohistochemistry/immunofluorescence analysis of MYC (brown signal) expression in the
GC showing that scatteredMYC+ cells are detected in CD20+ (cyan and red signals) cells within the Ki-67-low (purple and
green signals) area corresponding to the LZ.
(C) Triple-marker combined immunohistochemistry/immunofluorescence analysis of CD44 (cyan and red signals)
expression in the GC showing that CD44 expression is more intense in Ki-67-low (brown signal) B cells characterized by a
brighter CD20 expression (purple and green signals), corresponding with the LZ.
(D) Triple-marker combined immunohistochemistry/immunofluorescence analysis of CD54/ICAM-1 (cyan and red signals)
expression in the GC showing that CD54 signal is more intense in Ki-67-low (brown signal) area corresponding to the LZ,
where it marks both CD20+ (purple and green signals) and negative (arrowheads) cells. All the representative
microphotographs have a 2003 original magnification. Scale bars, 100 micrometers.
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at probing the transcriptome of GC-related aggressive B cell lymphomas in the attempt to trace tran-
scriptional clusters reminiscent of the two distinct GC microenvironments. We therefore applied the
DZ/LZ signature to a large dataset of 543 GC-DLBCL including DH cases treated with RCHOP or
RCHOP + bortezomib (RB-CHOP), in the context of the REMoDL-B clinical trial (Sha et al., 2019). The trial
had shown no significant benefit with the addition of bortezomib to R-CHOP, but represents a valuable
cohort for biomarkers of standard front-line treatment, as in the identification of features associated with
molecular high-grade (MHG) lymphomas (Sha et al., 2019). We found that according to the expression of
the DZ/LZ differential genes, two subgroups of GC-related lymphomas could be identified on unsuper-
vised clustering analysis: one characterized by a transcriptional profile resembling that of the spatial LZ
signature (LZ-like) and the other more related to the spatial DZ profile (DZ-like) (Figure 4A). This finding
indicated that the heterogeneity intrinsic to the gene expression profiles of GC-related aggressive lym-
phomas is at least in part organized according to DZ/LZ microenvironment-linked transcriptional
features.
Figure 3. Performance of the DZ/LZ 53-Genes Signature and of the 25-Genes Stromal Signature in Victora’s
Dataset (GSE38697)
(A and C) Venn diagrams representing the overlap of the two spatial signatures (the 53-genes differential DZ/LZ signature
and the 25-genes signature) with Victora’s DZ/LZ B cell signature. The 53-genes DZ/LZ signature (A) displays an overlap of
10 genes (3 upregulated in the DZ and 7 upregulated in the LZ) with the 441 genes of Victora’s DZ/LZ B cell signature,
whereas the 25-genes stromal signature (C) shows no overlapping genes.
(B and D) Unsupervised hierarchical clustering analysis based on the 53-genes DZ/LZ signature (B) and on the 25-genes
signature (D) in Victora’s dataset (genes are listed in rows, and samples are shown as columns).
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Notably, the LZ-like and DZ-like subgroups identified in the cohort of 543 lymphomas of GC origin showed
a significantly different enrichment for DH cases characterized by genetic rearrangement ofMYC and BCL2
or BCL6 and for MHG cases classified according to a gene expression classifier (Figures 4B and 4C) (Sha
et al., 2019). Indeed, the DZ-like cluster was positively enriched in DH and MHG cases when compared
with the LZ-like cluster. Consistently, the cases falling in the DZ-like cluster showed a significantly worse
overall survival (OS) when compared with the predominant LZ-like cluster (Figure 4D). Actually, the
Figure 4. Application of a Spatially Resolved 53-Genes Signature Discriminating DZ and LZ to 543 GC-Related
DLBCL and DH Cases (GSE117556)
(A) Unsupervised clustering analysis of the 543 GC-DLBCL and DH cases based on the DZ/LZ signature identifies two
distinct clusters (DZ-like and LZ-like).
(B and C) Bar plots showing the differential enrichment in molecular high-grade (MHG, B) and double-hit (DH, C) cases
between the DZ-like and LZ-like clusters.
(D) Survival analysis showing significantly different overall survival in the LZ-like and DZ-like clusters.
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prognostic difference of the two clusters was dependent on the presence of DH cases prominently contrib-
uting to the DZ-like cluster, as the exclusion of DH from the prognostic analysis resulted in a striking down-
sizing of the cluster (from n = 153 to n = 24).
To validate that our spatial DZ/LZ signature could identify DZ-like lymphomas, we extended our analysis by
applying the 53-genes DZ/LZ signature to the Burkitt lymphoma (BL) setting. We performed an integrated
analysis including DLBCL and BL samples from Sha’s dataset by applying unsupervised hierarchical clus-
tering. The analysis revealed that the majority of BLs clustered with MHG GCB-like DLBCL samples based
on shared gene expression profile resembling DZ phenotype (Figure S2). In particular, 56 of 70 BLs (80%)
were clustered in the DZ-like cluster according to the 53-genes DZ/LZ signature. This finding was of partic-
ular interest if we consider that BL represents a rather homogeneous disease as far as the biological fea-
tures of the malignant clone are concerned, and that the recently reported variability in BL immune land-
scape (Granai et al., 2020) may configure different microenvironment scenarios more similar to or distinct
from the immunologically cold DZ.
To further investigate the contribution of primarily stromal and immune cell transcripts to the clustering of
the 543GC-related lymphoma cases, we applied the 25-genes stromal signature obtained from the analysis
of ROI sub-compartments (Figure 5A). Interestingly, the 25-genes signature also subdivided the 543 GC-
related aggressive lymphoma cases into two distinct LZ-like and DZ-like clusters (Figure 5B) with signifi-
cantly different MHG and DH enrichment (Figures 5C and 5D), and the two clusters also showed signifi-
cantly different OS (Figure 5E). This finding revealed the possibility to discriminate GC-related lymphomas
differently enriched in MHG and DH according to stromal features, indicating that DH lymphomas, despite
a common GC origin with other non-DH GC-DLBCL display an immunological and mesenchymal microen-
vironment reminiscent of the GC DZ.
We finally addressed whether our 25-genes stromal signature was in part overlapping with two consoli-
dated stromal microenvironment signatures of prognostic significance identified by Lenz and colleagues
in DLBCL (Lenz et al., 2008). We therefore investigated the degree of overlap of the 25-genes DZ/LZ stromal
signature with Lenz’s stromal signatures and found that only one gene, CLU, was shared with the Stromal-1
and one gene, PECAM1, with the Stromal-2 signature (Figure S3). This result indicated that our immune/
mesenchymal DZ/LZ differential signature probed a different level of microenvironment heterogeneity
when compared with that of consolidated DLBCL stromal features.
DISCUSSION
B cells undergoing malignant transformation along lymphomagenesis receive an imprint from the trans-
forming environment in the form of genetic lesions and phenotypical skewing. In the case of GC-related
lymphomas, that imprint is traceable in gene rearrangement events promoted by AID mutational machin-
ery activity, and by the replicative stress induced in the DZ, potentially affecting the genetic and molecular
subtypes, that relate to the COO (Pasqualucci and Dalla-Favera, 2015). Within GC-DLBCL, the pathoge-
netic hypothesis that malignant B cell transformation may occur in either of the two functionally specialized
compartments of the GC, DZ and LZ, has found experimental support through evidences pointing to dif-
ferential expression of MHC I/II molecules, differential frequency of EZH2mutations (Ennishi et al., 2019b),
and differential expression of a subset of DZ/LZ-associated gene transcripts in different subsets of GCB
DLBCL (Ennishi et al., 2019b; Victora et al., 2012). MHC classes I and II expression is transcriptionally modu-
lated in the transition from the DZ to the LZ. Expression of MHC I/II cannot be exploited in the classification
of GCB DLBCL subsets given the strong selection pressure imposed on the lymphoma cells by the immune
system that causes recurrent extinction of these molecules from the surface of the malignant B cells
because of mutational events (Ennishi et al., 2019b). Similarly, the attempt to link MHC negativity to the
immunologically coldmicroenvironment of the DZ in GC-related DLBCL has beenmostly based on the pos-
itive enrichment of signatures obtained by DZ B cells purified according to DZ/LZ surface markers (Ennishi
et al., 2019b; Victora et al., 2012). Such B cell-centered approach, which has been successful in distinguish-
ing clusters of DLBCL and in separating DLBCL from more aggressive entities, lacked the role of features
representative of the in situ stromal and immune context that could affect the modulation/maintenance of
programs resulting from the cross talk between B cells and stromal elements. We have applied DSP to non-
neoplastic lymph nodeGCs to gain insight into the immune and stromal composition of the DZ and LZ, with
the aim of deriving a spatially resolved microenvironment signature contributed by B cells and non-B stro-
mal and immune cells, to probe DZ-/LZ-like microenvironment imprints in GC-related DLBCL and DH
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lymphomas. Along with a 53-genes signature including transcripts differentially expressed between DZ and
LZ ROIs, we derived a 25-genes signature composed of those differential genes significantly more repre-
sented in the GC DZ and LZ stromal, non-B, sub-compartments and contributed mostly by transcripts ex-
pressed in adjacent stromal/immune cells that were asymmetrically distributed between DZ and LZ areas.
The newly identified DZ/LZmicroenvironmental signatures were exploited to question the origin of a highly
heterogeneous set of GC-related aggressive B cell lymphomas. Our results establish the existence of two
Figure 5. Application of a 25-Genes Stromal Signature Discriminating DZ and LZ to 543 GC-Related DLBCL and
DH Cases (GSE117556)
(A) Unsupervised clustering of DZ and LZ ROIs according to 25 genes significantly more expressed in stromal
(CD20NGFR+ FDCs and CD20NGFR remaining stromal and immune cells) ROI masks when compared with B cell
(CD20+NGFR) masks (see Figure S1).
(B) Unsupervised clustering analysis of the 543 GC-DLBCL cases based on the 25-stromal/immune genes DZ/LZ signature
identifies two distinct clusters (DZ-like and LZ-like).
(C and D) Bar plots showing the differential enrichment in molecular high-grade (MHG, C) and double-hit (DH, D) cases
between the two clusters identified according to the 25-genes signature.
(E) Survival analysis showing significantly different overall survival in the LZ-like and DZ-like clusters identified according to
the 25-genes stromal signature.
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distinct tumor groups within GC-related aggressive B cell lymphomas, with those displaying a DZ-like
microenvironment profile strikingly enriched for DH lymphomas. Consistently, this same DZ-like group
showed strong positive enrichment for BL cases, indicating that MYC-driven lymphomagenesis in the
GC (Basso and Dalla-Favera, 2015; Dominguez-Sola et al., 2012) is preferentially related with a DZ-like
microenvironment.
Future studies will be needed to assess whether specific genetics of GC-type DLBCLmay associate with LZ-
and DZ-like microenvironment profiles, based on the preliminary observation that EZH2 mutations and
BCL2 translocations, which have been demonstrated to display higher DH scores than other subtypes
(Schmitz et al., 2018), showed a relative enrichment in DZ B cell signatures. Similar efforts should be placed
to establish possible differences in the microenvironmental context of EZB-MYCneg lymphomas from that
of EZB-MYC+ lymphomas, with the latter showing a worse prognosis (Wright et al., 2020).
The significant skewing in the distribution of DH cases in the DZ-like cluster provides preliminary insight
into the unique immune and stromal microenvironment featuring these peculiar lymphomas, the biology
and pathogenic trajectories of which are yet poorly understood. In summary, by applying Digital Spatial
Profiling we provide first-time evidence for the existence of a GC DZ/LZ immune and stromal microenviron-
ment signature able to cluster GC-related aggressive B cell lymphomas into twomain groups with different
response to standard chemo-immunotherapy regimens. In particular, our data provide experimental sup-
port for an origin from DZ GC B cells of highly aggressive DH lymphomas.
Limitations of the Study
A limitation of the experimental approach pursued in the analysis of segmented ROIs is represented by the
level of resolution in the discrimination between different cellular components. Indeed, in the GC sub-com-
partments, B cells intermingle tightly with mesenchymal elements, such as FDCs or other immune cells
including myeloid elements (e.g., GC macrophages). This tight interaction is responsible for the potential
transfer of myeloid or stromal cell transcripts to B cell sub-compartments. To overcome this limitation, we
attributed to B cell or stromal cell sub-compartments only those differentially expressed transcripts that
were significantly enriched in that specific sub-compartment. New analytical tools are needed to overcome
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Supplemental Information 1 
 2 
Figure S1, Related to Figure 1. Clustering of DZ and LZ ROIs according to the 53 differential genes assessed 3 
in different ROI masks as shown in Figure 1C. A) Clustering of the 53 genes discriminating DZ and LZ reveals 4 




Figure S2, Related to Figure 4. Unsupervised hierarchical clustering of Sha’s dataset (GSE117556) extended 7 
to Burkitt Lymphoma (BL) cases, according to the 53 genes DZ/LZ spatial signature. A) The heatmap 8 
representing z-score normalized values of the 53 genes reveals that the majority of BL (56 out of 70, 80%) are 9 




Figure S3, Related to Figure 5. Analysis of the overlap between the 25 genes DZ/LZ stromal signature and 12 
Lenz’s stromal signatures (Lenz et al., 2008). A) Only one gene, CLU, was shared with the Stromal-1 and one 13 
gene, PECAM1, with the Stromal-2 signature, indicating that a different level of heterogeneity is probed through 14 
the 25 genes DZ/LZ stromal microenvironment signature.   15 
 
 
Transparent Methods  16 
To investigate the immune and stromal composition of two spatially-resolved GC microenvironments, namely 17 
the DZ and LZ, multiplexed wide field immunofluorescence (IF) analysis was combined to ROIs definition and 18 
segmentation, and in situ mRNA analysis to screen four-micrometer thick tissue sections from formalin-fixed 19 
and paraffin-embedded reactive lymph nodes using a GeoMx Digital Spatial Profiler (DSP) (NanoString, 20 
Seattle WA) (Merritt et al., 2020). Samples were collected according to the Helsinki Declaration and the study 21 
was approved by the University of Palermo Institutional Review Board (approval number 09/2018).The 22 
following antibodies were adopted for 4-plex IF tissue imaging: mouse anti-human CD20 (L26 Novocastra, 23 
Leica Biosystems), mouse anti-human CD271 (NGFR, MRQ-21 Cell Marque), mouse anti-human SMA (ASM-24 
1 Novocastra, Leica Biosystems). Syto83 was used as nuclear counterstain in DSP IF-based ROI selection 25 
while DAPI was adopted for validation IF stainings.  26 
For the determination of the 87-plex customized TAP Human Immuno Oncology panel, mRNA binding DNA 27 
probes (5′ to 3′ 35- to 50-nt target-complementary sequences) conjugated with UV photocleavable indexing 28 
oligos were hybridized to the tissue as previously reported (Merritt et al., 2020). The UV photocleavable probes 29 
were released from each ROI according to custom masks for UV illumination and digitally counted using the 30 
NanoString nCounter Analysis System. For nCounter data analysis, digital counts from barcodes 31 
corresponding to mRNA probes were normalized to internal spike-in controls (ERCC). Moreover, a set of six 32 
internal housekeeping genes was included in the TAP Human Immuno Oncology panel to control for system 33 
variation including ROI size and cellularity (Decalf et al., 2019; Merritt et al., 2020). Seven negative control 34 
probes were adopted to evaluate and filter ROIs with a high degree on non-specific binding (none identified in 35 
this experiment). Normalized gene expression data relative to the ROIs analyzed in this study are reported in 36 
Table S4. Unsupervised hierarchical clustering of the ROIs was performed on the normalized counts using the 37 
pheatmap function of the homonymous R package with default parameters. Genes differentially expressed 38 
between LZ and DZ ROIs were identified by applying an empirical Bayes test using the Limma R package.  39 
CD20, CD44, CD54, H3, Ki-67, and MYC expression in GC DZ and LZ of the lymph nodes profiled by DSP 40 
was validated at the protein level using double- or triple marker immunostainings (Figure 2). Double- and triple-41 
marker immunostainings on reactive lymph nodes were performed as follows: four micrometers-thick sections 42 
from formalin fixed and paraffin-embedded lymph node biopsies were put onto positively-charged slides, 43 
deparaffinized and rehydrated. Sections underwent heath-induced antigen retrieval using Novocastra Epitope 44 
Retrieval Solution pH9 (Leica Biosystems). Slides underwent sequential rounds of incubation at room 45 
temperature for 1h with the following primary antibodies: mouse anti-human CD20 (1:100, clone L26, 46 
 
 
Novocastra, Leica Biosystems), rabbit anti-human Ki-67 (1:1000, Abcam), rabbit anti-human c-MYC (1:500, 47 
clone Y69, Abcam), goat anti-human Histone-H3 (1:150, Abcam), mouse anti-human CD44 (1:40, clone 48 
DF1485, Novocastra, Leica Biosystems), mouse anti-human CD54 (1:30, clone 23G12, Novocastra, Leica 49 
Biosystems). Primary antibodies binding was revealed by the use of specific secondary antibodies conjugated 50 
with either horseradish peroxidase (HRP) or fluorophores (Alexa 488, Alexa 568, Invitrogen; Opal 520, Opal 51 
620, Akoya Biosciences). 3,3’-diaminobenzidine (DAB) was used as chromogenic substrate for HRP. Slides 52 
were analyzed under a Zeiss Axioscope-A1 microscope equipped with bright field fluorescence module (Zeiss). 53 
Microphotographs were collected with a Zeiss Axiocam 503 Color digital camera using the Zen 2.0 imaging 54 
software (Zeiss). 55 
The spatial DZ/LZ signatures were tested in the following independent transcriptomic datasets: GSE38697; 56 
GSE117556. For both datasets we used normalized expression data provided by the Authors. To further 57 
validate the 53 genes DZ/LZ spatial signature in bona fide DZ-derived aggressive lymphomas, we integrated 58 
the 70 Burkitt Lymphoma samples (GSE69051) from Sha et al., with the DLBCL samples (GSE117556). Raw 59 
data from these samples were processed with the Limma R package to generate normalized values applying 60 
a quantile normalization. Where multiple probes represented the same gene, the gene expression was 61 
summarized with the maximum value. After performing z-score normalization, hierarchical clustering based on 62 
the spatially-resolved DZ/LZ 53 genes signature and/or on the 25 stromal genes signature was applied to 63 
identify clusters reflecting GC heterogeneity. Hierarchical clustering analysis was performed using Ward.D2 64 
and Euclidean distance. The rand-index measure was used to quantify the similarity of two clustering results. 65 
For survival analysis, we used Kaplan-Meier with log-rank tests to estimate overall survival between the 66 
identified clusters. Differences in patient characteristics were analyzed using the c2 test; a p-value <0.05 was 67 
set as the threshold for significance. To visualize the overlapped genes between the different signatures we 68 
applied Euler R package (https://cran.r-project.org/package=eulerr). All statistical analyses were performed 69 
using R statistical software package (v 3.6.0) (http://www.R-project.org). 70 
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